results for the six-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
million, a decrease of 4% YoY, mainly due to financial statement adjustment in accordance with new Thai accounting standards and decline in overall fruit juice market. Export branded sales continued to grow
Baht 64 million; and (2) cash inflows from net change in working capital of Baht 7 million, mainly due to lower trade receivables, inventories, and other receivables. Net cash used in investing
Summary of operations and the factors that make a significant change Summary of Operations for the Year 2019 Topic Annual Balance Change 2019 2018 2019 VS 2018 (MB) (MB) % Total Revenue 7,076.7 4,237.6
Operating Results of the Company in Q2/2019 Q2/18 Q2/19 1H/18 1H/19 Change +/(-) (THB million) YoY 1H Operating Revenue 206 312 51% 405 599 48% Gross Profit 138 201 46% 273 389 42% EBITDA 49 95 94% 99 186 88
Company’s Performance Unit : Million Baht For the 3 months Change between QoQ Change between YoY For the 9 months Change between YoY Q3/18 Q2/18 Q3/17 Amount % Amount % Sep. 18 Sep. 17 Amount % Revenues from
expense cuts in all areas. Administrative cost increased due to the shutdown of the KCEI plant, which was related to labor compensation payments, factory shutdown expense, and a change of monthly
December 2019 increased by 7% yoy due to higher profit accumulated. 31 Dec. 31 Dec. % Change Dec 19 Unit : THB million 2019 2018 Dec 18 Cash and temporary investments 223.42 539.83 -59% Trade receivables
Profits increased 17% to THB 632m in Q3 2017 from THB 540m in Q3 2016. Net Profit increased 35% to THB 769m in Q317 from THB 569m in Q316, due to higher operating profits and exchange gain in Q317. Quarter
decrease in total revenue 3.4% and can be summarized as following table. Description Total Revenue (MB) Y-O-Y Change Increase/(Decrease) Note 2016 2017 Sales 919.8 882.2 -4.1% The sales volume decreases as